Kristie Nowak, MD
Infectious Disease · Memphis, TNNPI 1275598781
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,507 of the $2,497 with a category attached, or 60.4%. 13 manufacturers reported payments, led by Shionogi Inc at 42.5% of the total. Reporting peaked in 2019 at $1,514 and has fallen 73.7% since, to $398 in 2025.
Across 77 payments — averaging $32.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$1K
- Tetraphase Pharmaceuticals, Inc.$512
- La Jolla Pharmaceutical Company$373
- Merck$201
- Astellas Pharma US Inc$69
- Theratechnologies Inc.$59
- plus $222 from 7 others
What the payments were for
- Travel & lodging$98639%
- Food & beverage$1,50760%
- Gifts$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 9 | $1,061 |
| Tetraphase Pharmaceuticals, Inc. | 19 | $512 |
| La Jolla Pharmaceutical Company | 17 | $373 |
| Merck | 15 | $201 |
| Astellas Pharma US Inc | 3 | $69 |
| Theratechnologies Inc. | 3 | $59 |
| Paratek Pharmaceuticals, Inc. | 2 | $50 |
| Teleflex LLC | 1 | $38 |
| Gilead | 2 | $37 |
| AbbVie(2 entities) | 2 | $35 |
| Melinta Therapeutics, LLC | 2 | $29 |
| Insmed, Inc. | 1 | $19 |
| Medela LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xerava$276
How this compares
$2,497 in reported general payments places this provider in the 80th percentile of 156 infectious disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Memphis
- Michael GelfandMemphis$486K
- Kerry ClevelandMemphis$426K
- Stephen ThrelkeldMemphis$27K
- Imad OmerMemphis$22K
- Margarita LamotheMemphis$12K
- Daniel MurrellMemphis$12K
- James DaleMemphis$8K
- Michael ThrelkeldMemphis$5K
- Shirin MazumderMemphis$2K
- Chiemeziem NwanyanwuMemphis$899
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.